Article Details

Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data

Retrieved on: 2021-04-02 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data. View article details on hiswai:

Excerpt

If eventually approved, the longer dosing interval could offer a convenience that further sets Eylea apart from Roche and Novartis' rival VEGF inhibitor ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo